ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 93 of 97 for:    calcium cation

The Effects of Estrogen Replacement Therapy in Postmenopausal Women With Hypercalciuria and Low Bone Mass

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01928082
Recruitment Status : Terminated (The fellow conducting the recruitment and screening left the institution)
First Posted : August 23, 2013
Results First Posted : March 7, 2018
Last Update Posted : December 10, 2018
Sponsor:
Information provided by (Responsible Party):
University of Chicago

Brief Summary:
The purpose of this study is to assess if estrogen replacement normalizes urinary calcium excretion in postmenopausal women with hypercalciuria and low bone mass and to assess for differences in response to estrogen replacement in women with familial hypercalciuria compared to nonfamilial hypercalciuria.

Condition or disease Intervention/treatment Phase
Hypercalciuria Hypercalciuria, Familial Idiopathic Osteopenia Osteoporosis Drug: Transdermal estradiol Phase 2

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Effects of Estrogen Replacement Therapy in Postmenopausal Women With Hypercalciuria and Low Bone Mass
Actual Study Start Date : August 1, 2013
Actual Primary Completion Date : August 1, 2014
Actual Study Completion Date : August 1, 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bone Density

Arm Intervention/treatment
Experimental: Transdermal estradiol
Transdermal estradiol 0.05 mg/day for 4 weeks, followed by 0.10 mg/day for 4 weeks
Drug: Transdermal estradiol
4 weeks of Vivelle-Dot 0.05 mg/day followed by 4 weeks of Vivelle-Dot 0.10 mg/day
Other Names:
  • Vivelle-Dot 0.05 mg/day
  • Vivelle-Dot 0.10 mg/day




Primary Outcome Measures :
  1. Absolute Change in 24 Hour Urinary Calcium Excretion [ Time Frame: 4 weeks, 8 weeks ]
    0 participants were measured because the study was terminated


Secondary Outcome Measures :
  1. Serum 1,25-dihydroxyvitamin D3 [ Time Frame: 4 weeks, 8 weeks ]
    0 participants were analyzed because the study was terminated

  2. Serum Bone Morphogenetic Protein 2 [ Time Frame: 4 weeks, 8 weeks ]
    Not available because the study was terminated

  3. Serum Sclerostin [ Time Frame: 4 weeks, 8 weeks ]
    Not available because the study was terminated


Other Outcome Measures:
  1. Serum Estradiol [ Time Frame: 4 weeks, 8 weeks ]
    Not available because the study was terminated

  2. Serum Total Calcium [ Time Frame: 4 weeks, 8 weeks ]
    Not available because the study was terminated

  3. Calculated Serum Ionized Calcium [ Time Frame: 4 weeks, 8 weeks ]
    Not available because the study was terminated

  4. Calculated Tubular Resorption of Calcium [ Time Frame: 4 weeks, 8 weeks ]
    Not available because the study was terminated

  5. Serum 25 Hydroxyvitamin D [ Time Frame: 4 weeks, 8 weeks ]
    Not available because the study was terminated

  6. Serum Parathyroid Hormone [ Time Frame: 4 weeks, 8 weeks ]
    Not available because the study was terminated

  7. Serum Phosphorus [ Time Frame: 4 weeks, 8 weeks ]
    Not available because the study was terminated

  8. Serum Osteocalcin [ Time Frame: 4 weeks, 8 weeks ]
    Not available because the study was terminated

  9. Serum Bone-specific Alkaline Phosphatase [ Time Frame: 4 weeks, 8 weeks ]
    Not available because the study was terminated

  10. Serum C-telopeptides of Type 1 Collagen [ Time Frame: 4 weeks, 8 weeks ]
    Not available because the study was terminated

  11. Serum Procollagen Type 1 N-terminal Propeptide [ Time Frame: 4 weeks, 8 weeks ]
    It is not available because the study was terminated



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 69 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Postmenopausal women
  • Diagnosis of hypercalciuria
  • Diagnosis of low bone mass
  • Vitamin D replete (serum 25-hydroxyvitamin D level >35 ng/mL)

Exclusion Criteria:

  • Secondary causes of hypercalciuria (primary hyperparathyroidism, sarcoidosis, vitamin D excess, malignant neoplasm, and renal tubular acidosis)
  • Other metabolic bone disease (primary hyperparathyroidism, hyperthyroidism, hypercortisolemia, severe gastrointestinal disorders, liver cirrhosis, renal failure (Cr >1.5), active malignancy including multiple myeloma, rheumatological diseases, and Paget's disease of bone)
  • Use of medications affecting bone and calcium metabolism (corticosteroids in the previous 3 months, suppressive dose of thyroid hormone, calcium channel blockers, anti-convulsants, aromatase inhibitors, thiazolidinediones, and cyclosporine A)
  • History of coronary artery disease
  • Breast cancer or suspected estrogen-dependent neoplasia
  • Previous venous thromboembolic event
  • Stroke
  • Active liver disease
  • Tobacco use within the past 6 months
  • Negative colonoscopy within the previous 10 years or sigmoidoscopy within the previous 5 years
  • Negative mammogram within the previous 2 years
  • Negative Pap smear within the previous 3 years in women < or = 65 years old with an intact cervix
  • No vaginal bleeding within the prior 5 months.
  • Age > or = 70
  • > or = 20 years since last menstrual period or use of hormone replacement therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01928082


Locations
United States, Illinois
The University of Chicago
Chicago, Illinois, United States, 60637
Sponsors and Collaborators
University of Chicago
Investigators
Principal Investigator: Murray J Favus, MD University of Chicago

Publications:

Responsible Party: University of Chicago
ClinicalTrials.gov Identifier: NCT01928082     History of Changes
Other Study ID Numbers: 12-0062
First Posted: August 23, 2013    Key Record Dates
Results First Posted: March 7, 2018
Last Update Posted: December 10, 2018
Last Verified: October 2018

Keywords provided by University of Chicago:
Hypercalciuria, Familial Idiopathic
Hypercalciuria
Osteopenia
Osteoporosis
Postmenopausal women

Additional relevant MeSH terms:
Osteoporosis
Bone Diseases, Metabolic
Hypercalciuria
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Urological Manifestations
Signs and Symptoms
Estradiol
Polyestradiol phosphate
Estrogens
Estradiol 3-benzoate
Estradiol 17 beta-cypionate
Estradiol valerate
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Contraceptive Agents
Reproductive Control Agents
Contraceptive Agents, Female